Saturday 17 October 2026
Export DYN’s income statement to Excel — free account
Dyne Therapeutics, Inc.
In the quarter to June 2026, EPS fell 11.3%, free cash flow fell 39.1% and total debt rose 116.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
14.25
1.04
−6.80%
Follow DYN
Dyne Therapeutics, Inc. (DYN) P/E ratio
Dyne Therapeutics, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| DNLI Denali Therapeutics Inc. compare | n/m |
| CELC Celcuity, Inc. compare | n/m |
| BEAM Beam Therapeutics Inc. compare | n/m |
| RCUS Arcus Biosciences, Inc. compare | n/m |
| ZLAB Zai Lab Limited Unsponsored ADR compare | n/m |
| DYN Dyne Therapeutics, Inc. | n/m |
| ELVN Enliven Therapeutics, Inc. compare | n/m |
| PGEN Precigen, Inc. compare | n/m |
| NRIX Nurix Therapeutics, Inc. compare | 9.7× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)